NasdaqCM - Nasdaq Real Time Price USD

BioLineRx Ltd. (BLRX)

3.6400

+0.4300

+(13.40%)

At close: May 20 at 4:00:01 PM EDT

BioLineRx to Report First Quarter 2025 Results on May 27, 2025

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it will release its unaudited financial results for the quarter ended March 31, 2025 on Tuesday, May 27, 2025, before the U.S. markets open.

PR Newswire 21 hours ago

BLRX
+13.40%
BLRX: 2024 Financial Results

By John Vandermosten, CFA NASDAQ:BLRX READ THE FULL BLRX RESEARCH REPORT BioLineRx Ltd. (NASDAQ:BLRX) reported full-year 2024 results, with revenues reaching $28.9 million. As the company completes its commercialization transition of Aphexda (motixafortide) to Gamida Cell, its focus is shifting to replenishing its pipeline with a new development asset. Management reiterated their objective of

Zacks Small Cap Research last month

BLRX
+13.40%
BioLine Rx Ltd (BLRX) Q4 2024 Earnings Call Highlights: Strategic Licensing and Market ...

BioLine Rx Ltd (BLRX) secures significant licensing deals and investments, while navigating operational challenges and focusing on oncology and rare diseases.

GuruFocus.com last month

BLRX
+13.40%
BioLineRx Reports 2024 Financial Results and Provides Corporate Update

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today reported its audited financial results for the year ended December 31, 2024, and provided a corporate update.

PR Newswire last month

BLRX
+13.40%
BioLineRx to Report 2024 Annual Results on March 31, 2025

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it will release its audited financial results for the year ended December 31, 2024 on Monday, March 31, 2025, before the U.S. markets open.

PR Newswire last month

BLRX
+13.40%
BLRX: Aphexda Transition Progressing

By John Vandermosten, CFA NASDAQ:BLRX READ THE FULL BLRX RESEARCH REPORT BioLineRx Ltd. (NASDAQ:BLRX) continues its commercialization transition activities for Aphexda as responsibilities for marketing shift from BioLine’s internal team to Ayrmid’s subsidiary Gamida Cell. Gamida cell is commercializing Omisirge, a cell therapy for treating blood cancers in patients who need a stem cell

Zacks Small Cap Research 2 months ago

BLRX
+13.40%
BioLineRx Issues Letter to Shareholders

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today issued the following letter to shareholders.

PR Newswire 3 months ago

BLRX
+13.40%
BioLineRx Announces Change to Ratio of American Depositary Shares to Ordinary Shares

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, announced today that its Board of Directors has approved a change in the number of its ordinary shares represented by American Depositary Shares, issued by the Bank of New York Mellon as depositary, from 15 ordinary shares per ADS to 600 ordinary shares per ADS. The change in exchange ratio for the ADSs will have the same effect as a 1-for-40 reve

PR Newswire 3 months ago

BLRX
+13.40%
BioLineRx Announces $10 Million Registered Direct Offering

BioLineRx Ltd. (Nasdaq: BLRX) (TASE: BLRX) ("BioLineRx" or the "Company"), a development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it has entered into definitive agreements for the purchase of an aggregate of 50,000,000 of the Company's American Depositary Shares (ADSs) (or ADS equivalents) and accompanying warrants to purchase up to an aggregate of 50,000,000 ADSs, at a purchase price of $0.20 per ADS (or per ADS equival

PR Newswire 4 months ago

BLRX
+13.40%
BLRX: Ayrmid Assumes Commercialization Efforts

By John Vandermosten, CFA NASDAQ:BLRX READ THE FULL BLRX RESEARCH REPORT A few days prior to its third quarter earnings report, BioLineRx Ltd. (NASDAQ:BLRX) announced a commercialization agreement with Ayrmid Ltd. and its subsidiary Gamida Cell Ltd. BioLineRx will grant Ayrmid rights to commercialize Aphexda (motixafortide) across all indications except in solid tumors and in all territories

Zacks Small Cap Research 5 months ago

BLRX
+13.40%
BioLine Rx Ltd (BLRX) Q3 2024 Earnings Call Highlights: Revenue Surge and Strategic Shifts

BioLine Rx Ltd (BLRX) reports a significant revenue increase and outlines strategic plans amid operational changes and market challenges.

GuruFocus.com 5 months ago

BLRX
+13.40%
BioLineRx Reports Third Quarter 2024 Financial Results and Provides Update on Transformation to Drive Shareholder Value

BioLineRx Ltd. (NASDAQ/TASE: BLRX), a development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today reported its unaudited financial results for the third quarter ended September 30, 2024, and provided updates on strategic actions designed to drive shareholder value.

PR Newswire 5 months ago

BLRX
+13.40%
BioLineRx, Ayrmid enter license agreement for motixafortide through Gamida Cell

BioLineRx (BLRX) and Ayrmid, the parent company of Gamida Cell (GMDA), announced that the companies entered into a license agreement for motixafortide, BioLineRx’s FDA-approved stem cell mobilization agent indicated in combination with filgrastim for collection and subsequent autologous transplantation in patients with multiple myeloma. Under the terms of the agreement, BioLineRx granted Ayrmid an exclusive license to develop and commercialize Aphexda across all indications, excluding solid tumo

TipRanks 5 months ago

BLRX
+13.40%
BioLineRx and Ayrmid Ltd. Enter into Exclusive License Agreement to Commercialize APHEXDA® (motixafortide) through Gamida Cell Ltd.

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, and Ayrmid Ltd. ("Ayrmid"), the parent company of Gamida Cell Ltd., today announced that on November 20, 2024, the companies entered into a license agreement for motixafortide (commercially sold in the U.S. as APHEXDA®), BioLineRx's FDA-approved stem cell mobilization agent indicated in combination with filgrastim (G-CSF) for collection and subs

PR Newswire 5 months ago

BLRX
+13.40%
BioLineRx to Report Third Quarter 2024 Results on November 25, 2024

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it will release its unaudited financial results for the third quarter ended September 30, 2024 on Monday, November 25, 2024, before the U.S. markets open.

PR Newswire 5 months ago

BLRX
+13.40%
BioLineRx Announces Oral Presentation on Data from Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease at ASH 2024

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that an abstract including the initial results from a Phase 1 clinical trial evaluating motixafortide as monotherapy and in combination with natalizumab for CD34+ hematopoietic stem cell (HSC) mobilization for gene therapies in sickle cell disease (SCD) was accepted for oral presentation at the 66th American Society of Hematology

PR Newswire 6 months ago

BLRX
+13.40%
BioLineRx Announces USPTO Allowance of New Composition of Matter Patent on Motixafortide

BioLineRx Ltd. (NASDAQ/TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for a patent, titled, "COMPOSITION OF BL-8040," which covers the composition of motixafortide (APHEXDA®/BL-8040). The patent strengthens BioLineRx's robust intellectual property (IP) estate and extends its patent protection on motixafortide in th

PR Newswire 6 months ago

BLRX
+13.40%
BioLineRx Launches 'Mobilization Matters': A Digital Resource for People with Multiple Myeloma Preparing for Stem Cell Collection

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced the launch of Mobilization Matters, a digital resource for people with multiple myeloma who are preparing for stem cell collection for an autologous stem cell transplant. Launched on Apheresis Awareness Day, this platform offers patient stories, educational resources, and more to support those undergoing this critical phase of tr

PR Newswire 7 months ago

BLRX
+13.40%
BLRX: On Track for 60% Formulary Placement

By John Vandermosten, CFA NASDAQ:BLRX READ THE FULL BLRX RESEARCH REPORT BioLineRx Ltd. (NASDAQ:BLRX) almost doubled motixafortide product sales sequentially in 2Q:24. The second quarter’s $1.8 million in sales coincided with formulary placement of 37% of targeted centers. Product gross margin was 95%, rising slightly over 1Q:24. The company expects to reach formulary status of 60% of the top 80

Zacks Small Cap Research 8 months ago

BLRX
+13.40%
BioLineRx Reports Second Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today reported its unaudited financial results for the second quarter ended June 30, 2024, and provided recent corporate and portfolio updates.

PR Newswire 8 months ago

BLRX
+13.40%

Performance Overview

Return	BLRX	TA-125 (^TA125.TA)
YTD	-56.67%	+9.62%
1-Year	-85.32%	+34.67%
3-Year	-92.83%	+37.22%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

BioLineRx Ltd. (BLRX)

BioLineRx to Report First Quarter 2025 Results on May 27, 2025

BLRX: 2024 Financial Results

BioLine Rx Ltd (BLRX) Q4 2024 Earnings Call Highlights: Strategic Licensing and Market ...

BioLineRx Reports 2024 Financial Results and Provides Corporate Update

BioLineRx to Report 2024 Annual Results on March 31, 2025

BLRX: Aphexda Transition Progressing

BioLineRx Issues Letter to Shareholders

BioLineRx Announces Change to Ratio of American Depositary Shares to Ordinary Shares

BioLineRx Announces $10 Million Registered Direct Offering

BLRX: Ayrmid Assumes Commercialization Efforts

BioLine Rx Ltd (BLRX) Q3 2024 Earnings Call Highlights: Revenue Surge and Strategic Shifts

BioLineRx Reports Third Quarter 2024 Financial Results and Provides Update on Transformation to Drive Shareholder Value

BioLineRx, Ayrmid enter license agreement for motixafortide through Gamida Cell

BioLineRx and Ayrmid Ltd. Enter into Exclusive License Agreement to Commercialize APHEXDA® (motixafortide) through Gamida Cell Ltd.

BioLineRx to Report Third Quarter 2024 Results on November 25, 2024

BioLineRx Announces Oral Presentation on Data from Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease at ASH 2024

BioLineRx Announces USPTO Allowance of New Composition of Matter Patent on Motixafortide

BioLineRx Launches 'Mobilization Matters': A Digital Resource for People with Multiple Myeloma Preparing for Stem Cell Collection

BLRX: On Track for 60% Formulary Placement

BioLineRx Reports Second Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates

Performance Overview